M3 Biotechnology Plans Phase 1 Clinical Trial of Alzheimer’s Regenerative Therapy

M3 Biotechnology Plans Phase 1 Clinical Trial of Alzheimer’s Regenerative Therapy
M3 Biotechnology will test a regenerative therapy for Alzheimer’s in a Phase 1 clinical trial. The Seattle-based company designed NDX-1017 to slow or stop the progression of the disease, and perhaps reverse it, by restoring lost nerve cell connections in the brain. “Current drugs on the market for Alzheimer’s patients offer only symptomatic relief, whereas we anticipate

Knowledge is power when living with alzheimers.

Get access to the web’s leading Alzheimer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

One comment

Leave a Comment

Your email address will not be published. Required fields are marked *